VERV (Verve Therapeutics) COGS-to-Revenue : 0.00 (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Verve Therapeutics COGS-to-Revenue?

Verve Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2025 was $0.00 Mil. Its Revenue for the three months ended in Mar. 2025 was $32.98 Mil.

Verve Therapeutics's COGS to Revenue for the three months ended in Mar. 2025 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Verve Therapeutics's Gross Margin % for the three months ended in Mar. 2025 was N/A%.

Verve Therapeutics COGS-to-Revenue Historical Data

The historical data trend for Verve Therapeutics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verve Therapeutics COGS-to-Revenue Chart

Verve Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

Verve Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Verve Therapeutics COGS-to-Revenue Calculation

Verve Therapeutics's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	32.332
	=	0.00

Verve Therapeutics's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	32.976
	=	0.00

Verve Therapeutics (NAS:VERV) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Verve Therapeutics's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 32.976
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Verve Therapeutics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Verve Therapeutics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Verve Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verve Therapeutics Inc (NAS:VERV) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Brookline Avenue, Suite 601, Boston, MA, USA, 02215

Website

https://www.vervetx.com

Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.

Executives

Joan Nickerson	officer: Chief Administrative Officer	C/O VERVE THERAPEUTICS, INC., 201 BROOKLINE AVENUE, SUITE 601, BOSTON MA 02215
Sekar Kathiresan	director, 10 percent owner, officer: Chief Executive Officer	500 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Andrew D. Ashe	officer: See Remarks	C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Allison Dorval	officer: Chief Financial Officer	C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Krishna Yeshwant	director, 10 percent owner	C/O GOOGLE VENTURES 2011, L.P., 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Fred T. Fiedorek	officer: Chief Medical Officer	55 BALDWIN LANE, PRINCETON NJ 08540
Andrew Bellinger	officer: Chief Scientific Officer	500 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Gv 2017 Gp, L.l.c.	10 percent owner	1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Alphabet Inc.	other: Member of 10% Group	1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Lonnel Coats	director	8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Fmr Llc	10 percent owner, other: See Remark 1	245 SUMMER STREET, BOSTON MA 02210
Alexander Cumbo	director	215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Burt A Adelman	director, 10 percent owner	DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Logos Global Management Lp	10 percent owner	1 LETTERMAN DRIVE, BLDG C, SUITE C3-350, SAN FRANCISCO CA 94129